Excise duty framework for cannabis products
https://policybase.cma.ca/link/policy13799

POLICY TYPE  Response to consultation
DATE  2017-12-07
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA Submission: Excise Duty Framework for Cannabis Products

Submission to the Government of Canada consultation on the proposed excise duty framework for cannabis products

December 7, 2017
Non-prescription availability of low-dose codeine products
https://policybase.cma.ca/link/policy13734

POLICY TYPE  Response to consultation
DATE  2017-11-7
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Bill C-45: The Cannabis Act
https://policybase.cma.ca/link/policy13723

POLICY TYPE: Parliamentary submission
DATE: 2017-08-18
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA Submission: Bill C-45: The Cannabis Act

Submission to the House of Commons Standing Committee on Health

August 15, 2017
CMA response to patented medicines regulations consultations
https://policybase.cma.ca/link/policy13690

POLICY TYPE  Response to consultation
DATE  2017-06-28
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents

Canada’s lower-risk cannabis use guidelines (LRCUG)
https://policybase.cma.ca/link/policy13726

POLICY TYPE  Policy endorsement
DATE  2017-05-26
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA’s Recommendations for Bill S-5: An Act to amend the Tobacco Act and the Non-smokers’ Health Act and to make consequential amendments to other Acts

https://policybase.cma.ca/link/policy13641

POLICY TYPE  Parliamentary submission
DATE  2017-04-07
TOPICS  Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA submission to the study of Bill C-37
https://policybase.cma.ca/link/policy13617

POLICY TYPE  Parliamentary submission
DATE  2017-04-06
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA Submission to the study of Bill C-37
An Act to amend the Controlled Drugs and Substances Act and to make related amendments to other Acts

Submission to the Senate Standing Committee on Legal and Constitutional Affairs
April 4, 2017
Consultation on the renewal of Federal Tobacco Control Strategy
https://policybase.cma.ca/link/policy13804

POLICY TYPE  Response to consultation
DATE  2017-04-05
TOPICS  Health care and patient safety
  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Position statement on prescription drug shortages in Canada
https://policybase.cma.ca/link/policy10756

POLICY TYPE
Policy document

LAST REVIEWED
2017-03-04

DATE
2013-05-25

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA POLICY
Position Statement on Prescription Drug Shortages in Canada

Pharmaceutical shortages are a problem, and not just in Canada. The United States is experiencing shortages of prescription drugs, and the situation is worsening. The problem is complex, involving issues of supply, demand, and regulatory policies. The Canadian Medical Association (CMA) has been working with stakeholders to address this issue. In 2013, the CMA released a position statement on prescription drug shortages in Canada.

The statement highlights the impact of shortages on patients, healthcare providers, and the overall healthcare system. It calls for a multi-faceted approach to addressing the problem, including increased transparency in the supply chain, better communication among stakeholders, and policies that support innovation and competition.

The CMA encourages healthcare providers to be proactive in managing shortages, such as by exploring alternative treatments and increasing patient education. It also recommends that governments and regulatory bodies work together to develop policies that prevent shortages from occurring in the first place.

The statement concludes with a call to action, urging all stakeholders to work together to ensure that patients have access to the medications they need. The CMA remains committed to advocating for policies that support a robust, reliable, and responsive drug supply system.

CMA Policybase - Canadian Medical Association